- Home
- PTHL vs MAIA Comparison
PTHL vs MAIA Comparison
Compare PTHL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- MAIA
- Stock Information
- Founded
- PTHL 1998
- MAIA 2018
- Country
- PTHL China
- MAIA United States
- Employees
- PTHL N/A
- MAIA N/A
- Industry
- PTHL
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- MAIA Health Care
- Exchange
- PTHL Nasdaq
- MAIA Nasdaq
- Market Cap
- PTHL 85.4M
- MAIA 46.7M
- IPO Year
- PTHL 2024
- MAIA 2022
- Fundamental
- Price
- PTHL $19.55
- MAIA $1.83
- Analyst Decision
- PTHL
- MAIA
- Analyst Count
- PTHL 0
- MAIA 0
- Target Price
- PTHL N/A
- MAIA N/A
- AVG Volume (30 Days)
- PTHL 781.5K
- MAIA 438.1K
- Earning Date
- PTHL 02-11-2025
- MAIA 08-08-2025
- Dividend Yield
- PTHL N/A
- MAIA N/A
- EPS Growth
- PTHL N/A
- MAIA N/A
- EPS
- PTHL N/A
- MAIA N/A
- Revenue
- PTHL $448,196.00
- MAIA N/A
- Revenue This Year
- PTHL N/A
- MAIA N/A
- Revenue Next Year
- PTHL N/A
- MAIA N/A
- P/E Ratio
- PTHL N/A
- MAIA N/A
- Revenue Growth
- PTHL N/A
- MAIA N/A
- 52 Week Low
- PTHL $1.32
- MAIA $1.40
- 52 Week High
- PTHL $22.34
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- MAIA 51.97
- Support Level
- PTHL N/A
- MAIA $1.80
- Resistance Level
- PTHL N/A
- MAIA $2.03
- Average True Range (ATR)
- PTHL 0.00
- MAIA 0.12
- MACD
- PTHL 0.00
- MAIA 0.02
- Stochastic Oscillator
- PTHL 0.00
- MAIA 53.49
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.